A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Brincidofovir Administered Intravenously in Healthy Adult Subjects
Chimerix, Inc.
28 participants
Jul 24, 2017
Interventional
Conditions
Summary
This is the second clinical study administering a new intravenous formulation of BCV. BCV has been studied in hundreds of patients as an oral formulation for the treatment of adenovirus and for the treatment and prevention of cytomegalovirus following stem cell transplantation. This second IV BCV study will investigate the safety and tolerability following multiple ascending doses to healthy subjects to observe how the new formulation compares to placebo and the oral formulations.
Eligibility
Inclusion Criteria6
- willing and able to provide written informed consent
- vasectomized male or female of non-childbearing potential
- non-tobacco/non-nicotine user in the past 6 months
- body weight greater than 50kg
- BMI from 18-32 kg/m2
- no significant medical history
Exclusion Criteria5
- child bearing potential
- investigational drug or clinical study in past 30 days
- positive for HBV, HCV, HIV.
- had any infection within past 2 weeks
- history of chronic liver disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
4 cohorts Intravenous (IV) brincidofovir (BCV) 10 mg or IV placebo administered over 2 hours, twice per week (BIW)-3 active and 1 placebo. Subjects in BIW cohorts will be dosed on Day 1, Day 4, Day 8 and Day 11 (i.e., 1.5 weeks). IV BCV 20 mg or IV placebo administered over 2 hours, once a week (QW)-6 active and 2 placebo. Subjects in QW cohorts will be dosed on Day 1, Day 8, Day 15, Day 22 (i.e., 3 weeks). IV BCV 20 mg or IV placebo administered over 1 hour, QW-6 active and 2 placebo. Subjects in QW cohorts will be dosed on Day 1, Day 8, Day 15, Day 22 (i.e., 3 weeks) IV BCV 20 mg or IV placebo administered over 1 or 2 hours, BIW-6 active and 2 placebo. Subjects in BIW cohorts will be dosed on Day 1, Day 4, Day 8 and Day 11 (i.e., 1.5 weeks). The 1 or 2 hour infusion time will be determined by the Sponsor and Principal Investigator following safety and PK review from previous cohorts. All doses will be administered in the study clinic and will be recorded in the case report form.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617000928314